Poziotinib enrollment completed in previously treated EGFR cohort (cohort 1) of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® (eflapegrastim) Biologics License Application (BLA) was submitted to the FDA Q4 Revenues were $29.4 million , including $28.0 million in product sales;

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 21, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 7, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York .

Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent

Results are expected in the second half of 2019 HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 2, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today

Submission based on results from two large, positive pivotal trials Both pivotal trials successfully met their primary endpoint and all secondary endpoints ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a proprietary platform technology to maximize the

Spectrum will host a live webcast today at 4:30 p.m. EST / 1:30 p.m. PST HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 19, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S.

Primary endpoint of non-inferiority in the Duration of Severe Neutropenia (DSN) between ROLONTIS and pegfilgrastim was met No statistically significant differences in adverse event rates between treatment groups RECOVER is the second ROLONTIS Phase 3 study to meet the primary efficacy endpoint of

In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) This was the first prospective study to evaluate the effect of oral leucovorin in preventing or reducing

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 13, 2018-- Spectrum Pharmaceuticals Inc. , (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca , MD, FACP to

Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation (BTD) for poziotinib and expects a

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 1, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.S.

Veteran of the Biopharmaceutical Industry Joins as Company Advances Two Late-stage Oncology Therapies HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 18, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 27, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Spectrum will host a live webcast today at 4:30 p.m. Eastern/1:30 p.m. Pacific HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 24, 2018-- Spectrum Pharmaceuticals, Inc.

Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations Phase 2 study now includes four cohorts with each cohort being an independent study with pre-specified statistical hypotheses

The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a